{"entity":{"id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-9839(sc) For Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07229638 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 70 participants planned, started 2026-02-27 and due to reach its primary completion in 2027-04. Interventions recorded: SHR-9839(sc) For Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07229638","url":"https://clinicaltrials.gov/study/NCT07229638"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07229638","phase":"1/2","setting":"An Open-label, Multicenter Phase IB/II Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct07229638/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}